Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4229 trials
Conditions Metabolic Dysfunction-Associated Steatot...
Phase Not Applicable
Enrollment 1000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

Liver is an important organ in maintaining energy homeostasis. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is the most common chronic liver disease locally and globally. MASLD and type 2 diabetes mellitus (T2DM) are closely related with alarmingly high prevalence of MASLD in people with T2DM, along with the escalated risk of adverse clinical outcomes. Our group has reported that around 70% of people with T2DM have increased controlled attenuation parameter (CAP) suggestive of hepatic steatosis and one out of six had advanced liver fibrosis as evidenced by increased liver stiffness measurements (LSM). Despite its prevalence, close relationships and potential consequences, the mechanisms underlying the complex interconnections between MASLD and T2DM are not fully understood. MASLD is associated with a twofold higher risk of developing T2DM, independent of obesity and other common metabolic risk factors. This risk increases with the severity of MASLD, such that patients with more advanced stages of liver fibrosis are at a higher risk of developing T2DM. Moreover, the progression from hepatic steatosis to fibrosis is an important, yet not fully understood, step towards cirrhosis and end-stage liver disease. Identification of clinical predictors and biomarkers to select individuals with MAFLD for close monitoring is pivotal to prevent the sinister outcomes. To date, longitudinal cohorts with paired biobank focused on people with diabetes and comorbid MASLD for investigating the clinical courses and biomarkers for prediction of outcomes are lacking. We hypothesized that Hong Kong Chinese T2DM with comorbid steatotic liver disease have unique clinical courses and special biomarkers for predicting the progression to advanced liver fibrosis. The aims of this study are: 1) establish a prospective cohort of people with T2DM and comorbid steatotic liver disease accompanied with the setting up of a biobank; 2) elucidate the clinical courses and outcomes of Hong Kong Chinese T2DM with comorbid steatotic liver disease; 3) identify potential diagnostic markers of advanced liver fibrosis in people with T2DM and comorbid steatotic liver disease in Hong Kong. The primary outcome measure will be all-cause mortality and secondary outcome measure will be fatal and non-fatal CVD, heart failure, hospitalizations, NT-proBNP levels, and novel diagnostic markers of MASH in people with T2DM comorbid with MASLD.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: No intervention (observational study) — There is no intervention involved in this observational study.

Primary Outcomes

  • All-cause mortality (15 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-06-11
Completion: 2027-02-28
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 1000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Chinese University of Hong Kong
Contact Information
Study Contact:
Alice Pik Shan Kong, MD
+852 3505 2648
alicekong@cuhk.edu.hk
Alice Pik Shan Kong, MD
+852 3505 2648
alicekong@cuhk.edu.hk
Department of Medicine and Therapeutics, The Chinese University of Hong Kong (CUHK), Ward 3M, Diabetes and Endocrine Research Centre, 3/F Day Treatment Block and Children Wards (Old Block), Prince of Wales Hospital
Interventions
  • Other: No intervention (observational study) — There is no intervention involved in this observational study.
Study Locations (1 sites)
Department of Medicine and Therapeutics, The Chinese University of Hong Kong (CUHK), Ward 3M, Diabetes and Endocrine Research Centre, 3/F Day Treatment Block and Children Wards (Old Block), Prince of Wales Hospital, Hong Kong, New Territories 99977 Hong Kong
Eligibility Criteria
Inclusion Criteria: * T2DM. * Aged ≥ 18 years. * Able and willing to give Informed written consent. Exclusion Criteria: * Type 1 diabetes. * Terminal illness such as malignancy with limited life expectancy. * Any condition, as judged by the investigators, as ineligible to participate in this study.
Conditions Diabetes Mellitus, Type 2, Diabetic Card...
Phase Not Applicable
Enrollment 593
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

Background: Heart failure is a major cause of morbidity and mortality in diabetes mellitus, but its pathophysiology is poorly understood. Aim: To determine the prevalence and determinants of subclinical cardiovascular dysfunction in adults with type 2 diabetes (T2D). Plan: 518 asymptomatic adults (aged 18-75 years) with T2D will undergo comprehensive evaluation of cardiac structure and function using cardiac MRI (CMR) and spectroscopy, echocardiography, CT coronary calcium scoring, exercise tolerance testing and blood sampling. 75 controls will undergo the same evaluation. Primary hypothesis: myocardial steatosis is an independent predictor of left ventricular global longitudinal strain. Secondary hypotheses: will assess whether CMR is more sensitive to detect early cardiac dysfunction than echocardiography and BNP, and whether cardiac dysfunction is related to peak oxygen consumption. Expected value of results: This study will reveal the prevalence and determinants of cardiac dysfunction in T2D, and could provide targets for novel therapies.

Design

Study type: Observational Observational model: Case Control Time perspective: Cross Sectional

Interventions / Regimen

  • Diagnostic Test: Cardiovascular magnetic resonance (CMR) imaging and magnetic resonance spectroscopy — CMR scanning performed on a 3T MRI scanner. Standardised protocol incorporating cine functional assessment to determine LV mass, systolic function and left atrial volumes; global systolic strain and diastolic strain rates will be assessed by tagging and with tissue tracking analysis from cine images, adenosine rest and stress myocardial perfusion to assess reserve index and qualitative perfusion defects as previously described, aortic distensibility and pulse wave velocity to measure aortic stiffness, delayed contrast enhancement for assessment of LV fibrosis and evidence of previous myocardial infarction. Myocardial and liver triglyceride content will be assessed using the modified Hepafat® sequence or 1H MR spectroscopy at the inter ventricular septum. DIXON technique for the quantification of visceral adiposity and subcutaneous adipose tissue.
  • Diagnostic Test: Transthoracic echocardiography — Comprehensive transthoracic echocardiography, including: tissue Doppler indices of diastolic filling and speckle tracking for systolic and diastolic strain/strain rate, exclusion of valvular abnormalities, assessment of LV size and function.
  • Diagnostic Test: Computed tomography coronary artery calcium scoring — Computed Tomography coronary calcium scoring to assess the presence of subclinical atherosclerosis and allow an estimate of atheroma burden in addition to epicardial adipose tissue characterisation and systolic strain.
  • Diagnostic Test: Cardiopulmonary exercise testing — Physician supervised incremental symptom limited cardiopulmonary exercise tolerance test with ECG and haemodynamic monitoring.
  • Diagnostic Test: Manganese-enhanced magnetic resonance imaging (MEMRI) — A subset of the participants will have cardiac MRI scanning with manganese-based contrast agent, lasting approximately 45-50 minutes. After localisers, baseline functions and native T1 maps have been acquired, Mangafodipir (0.1mL/kg) will be administered intravenously at 1ml/min, with additional T1 maps acquired every 2.5 min after administration of the contrast agent for up to 30 minutes.
  • Diagnostic Test: Ambulatory blood pressure monitoring — A 24-hour blood pressure monitor will be worn at the end of the visit to the following day.
  • Diagnostic Test: Accelerometer watch — Watch worn to collect free living physical activity data for 7 days.
  • Diagnostic Test: Blood tests — Collection of blood samples from each participant to characterise the participant's health status and to develop a proteomic signature of early heart failure.

Primary Outcomes

  • Prevalence of early heart failure in type 2 diabetes (5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2017-10-24
Completion: 2029-10-31
Eligibility
Age: 50 Years – 75 Years
Sex: ALL
Volunteers: true
Enrollment: 593 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Leicester
Principal Investigators:
  • Gerry P McCann, MD (PRINCIPAL_INVESTIGATOR) - University of Leicester
Contact Information
Study Contact:
Gerry P McCann, MD
01162583402
gpm12@le.ac.uk
Gaurav S Gulsin, MBChB(Hons)
01162583244
gg149@leicester.ac.uk
Gaurav S Gulsin, MRCP(UK)
University of Leicester
Interventions
  • Diagnostic Test: Cardiovascular magnetic resonance (CMR) imaging and magnetic resonance spectroscopy — CMR scanning performed on a 3T MRI scanner. Standardised protocol incorporating cine functional assessment to determine LV mass, systolic function and left atrial volumes; global systolic strain and diastolic strain rates will be assessed by tagging and with tissue tracking analysis from cine images, adenosine rest and stress myocardial perfusion to assess reserve index and qualitative perfusion defects as previously described, aortic distensibility and pulse wave velocity to measure aortic stiffness, delayed contrast enhancement for assessment of LV fibrosis and evidence of previous myocardial infarction. Myocardial and liver triglyceride content will be assessed using the modified Hepafat® sequence or 1H MR spectroscopy at the inter ventricular septum. DIXON technique for the quantification of visceral adiposity and subcutaneous adipose tissue.
  • Diagnostic Test: Transthoracic echocardiography — Comprehensive transthoracic echocardiography, including: tissue Doppler indices of diastolic filling and speckle tracking for systolic and diastolic strain/strain rate, exclusion of valvular abnormalities, assessment of LV size and function.
  • Diagnostic Test: Computed tomography coronary artery calcium scoring — Computed Tomography coronary calcium scoring to assess the presence of subclinical atherosclerosis and allow an estimate of atheroma burden in addition to epicardial adipose tissue characterisation and systolic strain.
  • Diagnostic Test: Cardiopulmonary exercise testing — Physician supervised incremental symptom limited cardiopulmonary exercise tolerance test with ECG and haemodynamic monitoring.
  • Diagnostic Test: Manganese-enhanced magnetic resonance imaging (MEMRI) — A subset of the participants will have cardiac MRI scanning with manganese-based contrast agent, lasting approximately 45-50 minutes. After localisers, baseline functions and native T1 maps have been acquired, Mangafodipir (0.1mL/kg) will be administered intravenously at 1ml/min, with additional T1 maps acquired every 2.5 min after administration of the contrast agent for up to 30 minutes.
Study Locations (1 sites)
University of Leicester, Leicester, United Kingdom
Eligibility Criteria
Inclusion Criteria: * Participant is willing and able to give informed consent for participation in the study. * Male or Female, aged ≥18 and ≤75 years. * Diagnosed with Stable type 2 diabetes (determined by: i) formal diagnosis in GP case records, ii) a record of diagnostic oral glucose tolerance test OR glycated haemoglobin level ≥6.5%). Exclusion Criteria: * Angina pectoris or limiting dyspnoea (\>NYHA II), * Major atherosclerotic disease: Symptomatic CAD, history of myocardial infarction, previous revascularisation, stroke/transient ischaemic attack or symptomatic peripheral vascular disease. * Atrial fibrillation or flutter. * Moderate or severe valvular heart disease. * History of heart failure or cardiomyopathy. * Type 1 diabetes mellitus (T1DM). * Low fasting C-peptide levels suggestive of adult-onset T1DM. * Stage III-V renal disease (estimated glomerular filtration rate ≤30ml/min/1.73m2). * Absolute contraindications to CMR. Importantly, patients with subclinical CAD, and other common comorbidities such as obesity and hypertension, will not be excluded from this study. This will enable us to evaluate the contribution of CAD to myocardial dysfunction in diabetes and ensures our study group is representative of the general population with diabetes. Similarly, as mild dyspnoea is extremely common and non-specific participants with mild dyspnoea will be included.
Conditions Type 2 Diabetes
Phase Not Applicable
Enrollment 3000
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

This study is a post-marketing, multicenter, prospective, observational study designed to evaluate the efficacy and safety of Proline Plus Empagliflozin Tablets in the real-world clinical treatment of type 2 diabetes mellitus. The study does not interfere with routine clinical practice, and Proline Plus Empagliflozin Tablets may be used either as monotherapy or in combination with other therapeutic agents based on actual clinical needs.

Design

Study type: Observational Observational model: Other Time perspective: Prospective

Primary Outcomes

  • HbA1c <7.0% (at 24 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-05-30
Completion: 2027-10
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 3000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Contact Information
Study Contact:
Bi Yan
86+13655176388
biyan@nju.edu.cn
Ge Zhi Juan
86+18061758651
gzjyunduan@126.com
Shen Hongmei Shen Hongmei, Master Degree Candidate
19837622007
48762111@qq.cn
Xinyang Central Hospital
Interventions
N/A
Study Locations (2 sites)
Xinyang Central Hospital, Xinyang, Henan 464000 China
Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, Jiangsu 210000 China
Eligibility Criteria
Inclusion Criteria: * 1.Age ≥18 years, regardless of gender. 2.Clinically diagnosed with type 2 diabetes mellitus (per the Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes Mellitus \[2020 Edition\]). 3.Deemed suitable by the investigator for treatment with proline-containing gliflozin tablets (Hui You Jing) and being prescribed this medication for the first time. 4.Availability of glycated hemoglobin (HbA1c) test results within 4 weeks prior to enrollment. 5.Voluntary participation with signed informed consent. Exclusion Criteria: \- 1.History of moderate to severe renal impairment (eGFR \<30 mL/min/1.73 m²), end-stage renal disease, or dialysis. 2.Acute or chronic metabolic acidosis, including diabetic ketoacidosis. Severe allergy to gliflozin or any excipient of the study drug. 3.Current or recent (within 1 month) participation in any other clinical trial. 4.Investigator judgment of unsuitability for the study.
Conditions Postoperative Pain
Phase Not Applicable
Enrollment 216
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

This observational study aims to determine the incidence and clinical characteristics of rebound-breakthrough pain after ultrasound-guided brachial plexus block in adult patients with type 2 diabetes mellitus. Adult patients undergoing elective upper-extremity surgery are divided into a type 2 diabetes group and a non-diabetic control group. Baseline clinical data and pain-related outcomes are collected after nerve block. This work may provide evidence for optimizing perioperative pain management for diabetic patients receiving brachial plexus block.

Design

Study type: Observational Observational model: Cohort Time perspective: Cross Sectional

Primary Outcomes

  • Incidence of postoperative rebound-breakthrough pain (Within 48 hours after brachial plexus block)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-09-20
Completion: 2026-09-20
Eligibility
Age: 18 Years – 80 Years
Sex: ALL
Volunteers: true
Enrollment: 216 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Second Hospital of Shanxi Medical University
Principal Investigators:
  • Li li Wang (STUDY_DIRECTOR) - Second Hospital of Shanxi Medical University
Contact Information
Study Contact:
Wen bo Wang
+8618636532676
1525565253@qq.com
Zheng Guo
+863513365790
guozheng713@yahoo.com
Second Hospital of Shanxi Medical University
Interventions
N/A
Study Locations (1 sites)
Second Hospital of Shanxi Medical University, Taiyuan, China
Eligibility Criteria
Inclusion Criteria: * Aged 18 years or older * Undergoing elective upper-extremity surgery * Planned for ultrasound-guided brachial plexus block with 0.375% ropivacaine * Able to cooperate with pain assessment and follow-up within 48 hours after block * Written informed consent obtained Exclusion Criteria: * Allergy or contraindication to amide-type local anesthetics * Pre-existing peripheral neuropathy of the affected upper limb * Chronic regular use of opioids before surgery * Coagulopathy or infection at the block puncture site * Cognitive dysfunction unable to complete NRS pain evaluation * Pregnancy or lactation * Incomplete clinical data expected during follow-up
Conditions Diabete Type 2
Phase NA
Enrollment 70
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

Evaluate from a clinical and microbiological point of view the effect of an adjunctive therapy based on a thermal-gelling device Pocket-X® Gel (Hyaluronic acid, Poloxamer, 2-Phenoxyethanol, Octedine HCL, Water), in the non-surgical treatment of periodontal defects, in a population of patients with T2DM compared to non-diabetic patients. Determine whether periodontal defect healing is clinically and microbiologically different between T2DM patients and non-diabetic patients; whether periodontal treatment and maintenance can lead to improvement of conditions and stability over time also for diabetic conditions.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: Gel therapy after non surgical therapy — The gel in use is a composition of Hyaluronic acid, Poloxamer, 2-Phenoxyethanol, Octedine HCL,Water (Pocket-X Gel Geistlich AG, Wolhusen, Switzerland). It is a patented liquid-to-gel device. Pocket-X® Gel is composed of: Poloxamer 407 with thermo-gelling properties, Octenidine, antimicrobial preservative, Hyaluronic acid to support tissue healing. It promotes gingival healing and prevents bacterial recolonization of periodontal pockets, forming a protective physical barrier, allows to postpone or avoid long, complex and painful surgeries, ensuring the success of periodontal treatment, delaying any surgical interventions.

Primary Outcomes

  • Clinical evaluation, in the test site and in the control site (for each of the two groups) of the periodontal index of: PPD in mm. (At baseline and after 2 weeks, 1 month, and 3 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-02-02
Completion: 2030-01
Eligibility
Age: 18 Years – 80 Years
Sex: ALL
Volunteers: true
Enrollment: 70 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Universita di Verona
Contact Information
Study Contact:
Alessia Pardo
+39 3494628471
Alessia.pardo@univr.it
Interventions
  • Device: Gel therapy after non surgical therapy — The gel in use is a composition of Hyaluronic acid, Poloxamer, 2-Phenoxyethanol, Octedine HCL,Water (Pocket-X Gel Geistlich AG, Wolhusen, Switzerland). It is a patented liquid-to-gel device. Pocket-X® Gel is composed of: Poloxamer 407 with thermo-gelling properties, Octenidine, antimicrobial preservative, Hyaluronic acid to support tissue healing. It promotes gingival healing and prevents bacterial recolonization of periodontal pockets, forming a protective physical barrier, allows to postpone or avoid long, complex and painful surgeries, ensuring the success of periodontal treatment, delaying any surgical interventions.
Study Locations (1 sites)
Alessia Pardo 3494628471 Alessia.pardo@univr.it, Verona, Italy 37134 Italy
Eligibility Criteria
Inclusion Criteria: Patients normally eligible for the visit and for the non-surgical type of treatment for periodontal defects: * patients with an age between 18 and 80; * patients with: (i) Asa status I (no functional impairment due to pathologies), (ii) patients with type 2 diabetes (T2DM) with: glycated hemoglobin level HbA1c between 6.5 and 8.0%, on dietary therapy and/or with hypoglycemic drugs in regular follow-up at the diabetes service; * patients with chronic periodontitis stage 3 or 4, according to the new classification of periodontal diseases \[Tonetti et al.\]), verified clinically and radiographically: patients will be selected with interdental clinical attachment level (CAL) at the site of greatest loss ≥3 mm to ≥2 non-adjacent teeth, probing depth (PPD) ≥5 mm, bleeding on probing (BoP) and horizontal and/or vertical radiographic bone loss. Exclusion Criteria: * Patients not eligible for the non-surgical type of treatment for periodontal defects: * patients with a positive history of diseases with functional impairment (ASA status 2,3,4) or severe handicaps that could limit the ability to attend appointments; * patients with uncontrolled/poorly controlled DM at the time of study selection (e.g. type 1 diabetes mellitus and secondary forms of diabetes); patients with uncontrolled and serious diabetic complications (cardiovascular, renal, hepatic and nervous); * poor compliance with treatment, with poor oral hygiene and motivation; * not signing informed consent by patients.
Conditions Diabetes Mellitus, Type 2, Lifestyle Ris...
Phase NA
Enrollment 126
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

We aim to provide medical nutritional therapy to patients with type 2 diabetes who are on oral hypoglycemic agents or on basal insulin only and monitor the glycemic response with flash glucose monitoring or self-monitoring of blood glucose. Specifically, this is a randomized, open-label, controlled study where half of the study participants will have FreeStyle Libre device on for 12 weeks and compare the change in glycated hemoglobin (HbA1c) value with the patients in the control group.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: FreeStyle Libre — Flash glucose monitoring + Education on lifestyle modification
  • Device: Blood glucose meter — Self monitoring of blood glucose + Education on lifestyle modification

Primary Outcomes

  • Change in HbA1c (Baseline to Month 3)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2021-03-23
Completion: 2023-03-23
Eligibility
Age: 19 Years – 80 Years
Sex: ALL
Volunteers: false
Enrollment: 126 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Seoul National University Hospital
Collaborators: Inje University, Kangbuk Samsung Hospital
Principal Investigators:
  • Young Min Cho, MD, PhD (PRINCIPAL_INVESTIGATOR) - Seoul National University Hospital
Contact Information
Study Contact:
Hun Jee Choe, MD
82-2-2072-1965
hunjeechoe@snu.ac.kr
Young Min Cho, MD, PhD
82-2-2072-1965
ymchomd@snu.ac.kr
Young Min Cho, MD, PHD
82-2-2072-1965
ymchomd@snu.ac.kr
Seoul National University Hospital
Interventions
  • Device: FreeStyle Libre — Flash glucose monitoring + Education on lifestyle modification
  • Device: Blood glucose meter — Self monitoring of blood glucose + Education on lifestyle modification
Study Locations (1 sites)
Seoul National University Hospital, Seoul, 110-744 South Korea
Eligibility Criteria
Inclusion Criteria: * Age 19-80 * Diagnosed with type 2 diabetes mellitus (DM) * Uncontrolled type 2 DM: HbA1c 7.0-10.0% * Signed informed consent Exclusion Criteria: * Diagnosed with other types of diabetes mellitus (i.e. Type 1 DM) * Use of prandial insulin * Change in diabetes medication in the preceding 3 months * Pregnant/lactating women * Addiction to drugs and alcohol * Use of medications that result in drug-induced hyperglycemia (i.e. steroid) * Severe liver disease * End-stage renal disease (i.e. on dialysis) * Unable to wear CGM devices due to dermatologic side effects (i.e. severe burn, inflammation, active skin infection, severe skin reactions, hypertrichosis, etc.) * Conditions that impact the stability of HbA1c measurement
Conditions Asthma
Phase NA
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this longitudinal observational study is to learn if impulse oscillometry (IOS) has an added value in asthma monitoring in adult asthma patients who are prescribed a change in asthma maintenance therapy. The main questions it aims to answer are: * Is there a difference in the change in IOS parameters and FEV1 respectively, stratified according to change in asthma control test? * Is there a difference in the change in IOS parameters and FEV1 respectively, stratified according to change in other questionnaire such as the asthma control questionnaire and the asthma quality of life questionnaire. * Are the proposed minimal clinically important differences (MCIDs) valid for short follow-up periods (3 - 6 months)? Participants will undergo lung function testing (full lung function, multiple breath nitrogen washout, impulse oscillometry) and questionnaires (asthma control test, asthma control questionnaire, asthma quality of life questionnaire), once during the baseline visit and once during the follow-up visit three to six months later.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Other: Full lung function — This includes spirometry, body plethysmography and single breath gas transfer test. These are all non-invasive physiological measurements / lung function tests. Measures flow volumes, lung volumes and gas transfer respectively.
  • Other: Multiple breath nitrogen washout — Non-invasive physiological measurement / lung function test. 100% oxygen is inhaled and the nitrogen concentration in the lungs is measured. This test gives information on the ventilation distribution in the lungs.
  • Other: Impulse oscillometry — Non-invasive physiological measurement / lung function test. This technique superimposes sound waves on tidal breathing. The patient can breathe normally trough the device, no forced respiratory maneuvers are required. It gives information on the reactance and resistance of the lung.

Primary Outcomes

  • Change in frequency dependance of resistance (FDR) stratified according to change in asthma control test (ACT) (Once at baseline and 3 - 6 months later during follow-up)
  • Change in area of reactance (AX) stratified according to change in asthma control test (ACT) (Once at baseline and 3 - 6 months later during follow-up)
  • Change in forced expiratory volume in 1 second (FEV1) stratified according to change in asthma control test (ACT) (Once at baseline and 3 - 6 months later during follow-up)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-09-01
Completion: 2026-04
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Universitair Ziekenhuis Brussel
Collaborators: Vrije Universiteit Brussel
Contact Information
Study Contact:
Shane Hanon, Prof. Dr. MD.
02 477 6841
Shane.Hanon@uzbrussel.be
Interventions
  • Other: Full lung function — This includes spirometry, body plethysmography and single breath gas transfer test. These are all non-invasive physiological measurements / lung function tests. Measures flow volumes, lung volumes and gas transfer respectively.
  • Other: Multiple breath nitrogen washout — Non-invasive physiological measurement / lung function test. 100% oxygen is inhaled and the nitrogen concentration in the lungs is measured. This test gives information on the ventilation distribution in the lungs.
  • Other: Impulse oscillometry — Non-invasive physiological measurement / lung function test. This technique superimposes sound waves on tidal breathing. The patient can breathe normally trough the device, no forced respiratory maneuvers are required. It gives information on the reactance and resistance of the lung.
Study Locations (1 sites)
Universitair Ziekenhuis Brussel, Brussels, 1090 Belgium
Eligibility Criteria
Inclusion Criteria: * Adult asthma patients with a scheduled consultation at the outpatient hospital to whom a step-up or step-down of their pharmacological asthma treatment is prescribed Exclusion Criteria: * Unstable asthma (defined as need for oral corticosteroids or (respiratory) antibiotic course in the 4 weeks before inclusion or any major medical issue in the 4 weeks before inclusion)
Conditions Chronic Rhinosinusitis With Nasal Polyps...
Phase Not Applicable
Enrollment 57
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

Mepolizumab is a biologic agent already approved for severe asthma. Recently, there is increasing evidence concerning the benefit of anti-IL5 treatments upon patients with nasal polyposis with or without severe asthma. The novelty of this project is that no biologic agent has yet been fully investigated to identify any biomarkers of response for patients with nasal polyps with or without asthma including sinonasal tissue remodeling a key element in the resultant histopathological changes of the inflammation. The investigation of airway remodeling of various locations (nose and bronchus) under mepolizumab treatment will be our primary objective on the long-term basis of 156 weeks of treatment. Endobronchial and nasal biopsies will be performed as routine care for tissue evauation and disease investigation for every patient. Besides, the united airways will provide better guidance for medical treatment of chronic rhinosinusitis (CRS) patients with nasal polyps (CRSwNP) and asthma. The initial idea is based on investigating the characteristics that could predict the effectiveness of mepolizumab on patients with nasal polyposis with or without asthma. Patients will receive 39 doses of mepolizumab for 156 weeks. An additional aim of this study is to identify characteristics of non-responders and responders to mepolizumab. Responders will be identified based on airway remodeling status, biomarkers in tissue and secretion samples and on the reduction of the need of surgery through Lund-Kennedy endoscopic score, Lund-Mackay score and patient's clinical status in the 6th, 12th and 36th month after the initiation of treatment. Regarding the unified airway system, nose and pharyngeal microbiome will be evaluated before and after 52 weeks of mepolizumab treatment in patients with nasal polyps whereas in patients with nasal polyps and asthma bronchus microbiome will also be evaluated. Lung samples will help gain information about the inflammatory profile and local microbiome of CRSwNP patients with asthma through molecular and cellular assays. The human Pharyngeal Microbiome might play a protective role in Respiratory Tract Infections and it has been reported that the microbiome provides critical signals to promote maturation of immune cells and differentiation of the tissue. Thus, we will make an effort to correlate microbiome of various locations with clinical and laboratory characteristics of responders and non-responders to mepolizumab treatment.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Drug: Mepolizumab 100 MG [Nucala] — subcutaneous injection once a month

Primary Outcomes

  • Change in Basement Membrane Thickness (through study completion, 156 weeks)
  • Change in smooth muscle cell mass (through study completion, 156 weeks)
  • Change in microbiome (through study completion, 156 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-02-23
Completion: 2027-03-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: Not specified
Enrollment: 57 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Aristotle University Of Thessaloniki
Collaborators: Department of Otorhinolaryngology, Head and Neck Surgery, George Papanikolaou Hospital, Department of Otorhinolaryngology, Democritus University of Thrace, Alexandroupolis, Department of Pulmonology, Democritus University of Thrace, Alexandroupolis, Respiratory Medicine Department, University of Ioannina, Faculty of Medicine, National and Kapodistrian University of Athens, Department of Allergy and Clinical Immunology, 424 General Military Training Hospital, Department of Otolaryngology, Head and Neck Surgery, Sotiria General Hospital
Principal Investigators:
  • Konstantinos Porpodis, Assoc Prof (PRINCIPAL_INVESTIGATOR) - Pulmonary Clinic, Aristotle University of Thessaloniki, George Papanikolaou Hospital
Contact Information
Study Contact:
Konstantinos Porpodis, Assoc Prof
00306944728818
kporpodis@yahoo.gr
Kalliopi Domvri, Dr
00306940904246
kdomvrid@auth.gr
Konstantinos Porpodis, Asist Prof
2313307258
kporpodis@yahoo.gr
Pulmonary Clinic of Aristotle University of Thessaloniki, George Papanikolaou Hospital
Interventions
  • Drug: Mepolizumab 100 MG [Nucala] — subcutaneous injection once a month
Study Locations (2 sites)
Pulmonary Clinic of Aristotle University of Thessaloniki, George Papanikolaou Hospital, Thessaloniki, Exochi 57010 Greece
University Pulmonary Clinic, George Papanikolaou Hospital, Thessaloniki, 57010 Greece
Eligibility Criteria
Inclusion Criteria: * Adult patients \> 18 years with bilateral Nasal Polyps * Symptoms VAS scores (for nasal obstruction, hyposmia, post-nasal drip, sneezing, rhinorrhea; 0-10 for each symptom) \> 24 in spite of treatment with standard of care treatment. * Patients with bilateral sinonasal polyps with a need for surgery as described by: Lund-Mackay score \> 4, Lund Kennedy score \> 6, a minimum total Nasal polyp score of 5 out of a maximum score of 8 at screening, ongoing symptoms for at least 12 weeks prior to screening, * Concerning patients with asthmatics with nasal polyps: subjects must have a medical history of asthma as confirmed by asthma related symptoms and by bronchodilator response (BDR) (GINA 2022) or positive methacholine challenge according to ERS guidelines. Exclusion Criteria: * Pregnant or nursing women, or women of child-bearing potential. * Biologic therapy (eg: Omalizumab, Mepolizumab, Reslizumab, Dupilumab) or previous treatment with Mepolizumab * Allergen immunotherapy in the past 6 months * Systemic corticosteroid treatment for other chronic conditions (i.e.: autoimmune disorders, tumors, etc) * Prior/concomitant therapy: use of immunosuppressive medication (including but not limited to: methotrexate, troleandomycin, cyclosporine, azathioprine, or any experimental anti-inflammatory therapy) within 3 months prior to Visit 1 and during the study period. * Evidence of active systemic immunodepression (i.e..: primary or secondary immunodeficiency) * History of malignancy of any organ system or any other serious co-morbidities defined by the treating physician. * Primary diagnosis of lung disease other than asthma (chronic obstructive lung disease (COPD), asthma-COPD overlap (ACO), interstitial lung disease, sarcoidosis, bronchiectasis, cystic fibrosis, primary ciliary dyskinesia, active tuberculosis, allergic bronchopulmonary aspergillosis (ABPA), current lung cancer or other blood, lymphatic or solid organ malignancy, autoimmune diseases of the skin, muscle-skeletal or gastrointestinal system needing systemic corticosteroids, immunosuppressants or biologic treatment as well as individuals with granulomatosis with polyangiitis (Wegener's granulomatosis) and eosinophilic granulomatosis polyangiitis (Churg-Strauss syndrome). * Nasal polyps' or Asthma exacerbation, within 12 weeks prior to screening that required oral corticosteroids over 3 days or hospitalization or emergency room visit.
Conditions Chronic Obstructive Lung Disease, Respir...
Phase Not Applicable
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to understand the role of oestrogen in patients with asthma and Chronic Obstructive Pulmonary Disorder (COPD). Therefore, what is the effect of oestrogen in these participants compared to controls (those without disease). The study hypothesises that oestrogen loss in patients with asthma and COPD causes accelerated lung function decline and changes to lung structure. It will investigate if this is mediated by inflammation, immune host response or elastin and collagen changes. It is an observational prospective cohort study aiming to recruit healthy controls, and people with asthma or COPD), and/or the menopause.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: No intervention — No Intervention

Primary Outcomes

  • Lung Function (FEV1 change from baseline) (Through study completion, minimum of 1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-12-01
Completion: 2028-11-01
Eligibility
Age: 18 Years – 99 Years
Sex: ALL
Volunteers: true
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Guy's and St Thomas' NHS Foundation Trust
Principal Investigators:
  • Mona Bafadhel (PRINCIPAL_INVESTIGATOR) - King's College London
Contact Information
Study Contact:
Gill Radcliffe Ms, MRes
+442071888070
gillian.radcliffe@gstt.nhs.uk
Chris Mwasuku
Christine.Mwasuku@gstt.nhs.uk
Gillian Radcliffe, MRES
+442071888070
gillian.radcliffe@gstt.nhs.uk
Guys & St Thomas NHS Foundation Trust
Interventions
  • Other: No intervention — No Intervention
Study Locations (1 sites)
Guys & St Thomas NHS Foundation Trust, London, SE1 7EH United Kingdom
Eligibility Criteria
Inclusion Criteria: 1. Men and women aged \&gt; 18 years. 2. For female participants: pre-menopausal, peri-menopausal and post-menopausal women can all be included. 3. Participants willing and able to give informed consent for participation in the study. 4. Healthy controls \&lt;10 pack year history (participants without Asthma or COPD). Exclusion Criteria: 1. Known or suspected current pulmonary tuberculosis, HIV (human immunodeficiency virus), Hepatitis B Virus, Hepatitis C Virus. 2. Alcohol or recreational drug abuse, is defined as when the use is harmful as per NHS definition. 3. History of psychiatric, medical, or surgical disorders. 4. Pregnant 5. Unable to provide written informed consent 6. History of advanced medical conditions with an expected prognosis of \&lt; 3 years. 7. Patients with a history of active cancer. 8. Patients on long term oxygen (ambulatory oxygen).
Conditions Asthma
Phase Not Applicable
Enrollment 60
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this observational study is to determine if using the SiA® (Systematic Intervention Agent) system can improve inhaler technique and medication adherence in adults with asthma who are already using Trimbow pMDI inhalers. Furthermore, it will be addressed if the SiA® system can be used to discriminate between patients, where increased inflammatory markers are caused by incorrect inhaler technique/adherence to medication or patients that have ongoing inflammation requiring adjustment of therapy. Potentially those who might become candidate for biological treatments. The main questions it aims to answer are: * Can the SiA® system improve inhaler use and medication adherence in asthma patients? * Does improving inhaler technique and adherence lead to better asthma control and reduced airway inflammation (measured by FeNO levels)? Participants will: * Use the SiA® system, which includes a smart inhaler cap (RespiPRO™) and a mobile app * Continue their prescribed Trimbow pMDI treatment for asthma. * Have their asthma control, lung function, and FeNO levels monitored at specific points over 1 year (3 months and 12 months). The study does not have a comparison group and all results will be compared to baseline.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • To evaluate the impact of the SiA® platform on the level of the type 2 inflammation biomarker FeNO (Change from baseline in FeNO at week 12 and 52.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-09-15
Completion: 2027-09
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Chiesi Pharma AB, Nordic
Collaborators: Briota ApS
Principal Investigators:
  • Johannes M Schmid, PhD, ass. professor (PRINCIPAL_INVESTIGATOR) - Aarhus University Hospital
Contact Information
Study Contact:
Nicolai Krogh, PhD
+4526850170
n.krogh@chiesi.com
Charlotte S Ulrik, MD, DMSc, FERS
+4538622177
charlotte.Suppli.Ulrik@regionh.dk
Copenhagen University Hospital-Hvidovre
Charlotte S Ulrik, charlotte.Suppli.Ulrik@regionh
Copenhagen University Hospital-Hvidovre
Interventions
N/A
Study Locations (2 sites)
Copenhagen University Hospital-Hvidovre, Hvidovre, Capital Region DK-2650 Denmark
Aarhus University Hospital, Aarhus, Central Jutland DK-8200 Aarhus N Denmark
Eligibility Criteria
Inclusion Criteria: 1. Patients ≥18 years of age. 2. Objectively verified leading diagnosis of asthma according to GINA 3. FeNO \>25 ppb. 4. Treated with Trimbow 87/5/9 pMDI for \>4 weeks before enrolment, 1. with prescribed rescue medication (SABA). 2. with and without prescription of a spacer. 5. Being literate Danish. 6. Having a personal Android/iOS phone and 4G/5G internet connection. 7. Comfortable using a smart phone and Bluetooth enabled Digital Devices. 8. Willingness to participate in the study, understand the written patient information and being able to provide written informed consent. Exclusion Criteria: 1. Participation in a clinical trial within 4 weeks prior to enrolment into the present study or planned enrolment in a clinical trial during the observational period. 2. Use of systemic corticosteroid as maintenance treatment. 3. Treated with biologics (that is monoclonal antibodies). 4. Concomitant diagnosis of COPD. 5. Lung cancer or history of lung cancer. 6. Respiratory tract infection/exacerbation within 4 weeks prior to enrolment. 7. Use of oral corticosteroids within 4 weeks before enrolment.
Conditions Asthma
Phase Not Applicable
Enrollment 140
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

Increasing evidence supports that the respiratory microbiota, including viral and bacterial microorganisms, play important roles in respiratory health and disease. Microbial patterns in airways may induce distinctive endotypes of asthma. Previous studies suggest host-microbiota interactions in children may account for the heterogeneity of endotypes and clinical presentations. However, information on such relationship is limited in adults. Furthermore, how the upper airway microbiome is related to asthma endotype and phenotype is not well understood. Knowledge of microbiota in the airway allows exploration of therapeutic manipulation of the microbiome and targeting the development of asthma prevention strategies and the optimization of asthma treatment.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: Treatment of asthma according to GINA guideline — Pharmacological treatment depending on level of control of asthma

Primary Outcomes

  • Microbiome pattern (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2021-06-22
Completion: 2027-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 140 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Chinese University of Hong Kong
Principal Investigators:
  • Fanny Ko, MD (PRINCIPAL_INVESTIGATOR) - Chinese University of Hong Kong
Contact Information
Study Contact:
Fanny Ko, MD
+852 35053133
fannyko@cuhk.edu.hk
David Hui, MD
+852 35053133
dschui@cuhk.edu.hk
Fanny WS KO, MD
fannyko@cuhk.edu.hk
Prince of Wales Hospital
Interventions
  • Other: Treatment of asthma according to GINA guideline — Pharmacological treatment depending on level of control of asthma
Study Locations (1 sites)
Prince of Wales Hospital, Shatin, Hong Kong
Eligibility Criteria
Inclusion Criteria: * Subjects aged between 18 and 80 years and have a diagnosis of asthma according to the Global Initiative for Asthma (GINA) document in 2020. * Asthma is defined as those with a consistent history and prior documented evidence of variable airflow obstruction, with evidence of an increase in FEV1 greater than 12% or 200 mL following bronchodilator or bronchial hyperresponsiveness on bronchial provocation testing, when stable. Exclusion Criteria: * Patients with respiratory diseases with other known respiratory diseases including chronic obstructive pulmonary disease, bronchiectasis, tuberculosis (TB)-destroyed lung parenchyma, history of lung resection and lung cancer * Individuals older than 40 years with a smoking history of more than 10 pack-years or significant biomass exposure * Patients currently randomized in other clinical studies * Pregnant women * Current smokers (who have not quit smoking in the past 1 year) * Systemic and intranasal antibiotics treatment within 4 weeks * Signs and symptoms of respiratory tract infections (upper or lower) within 4 weeks
Conditions Asthma Acute, Asthma Attack
Phase NA
Enrollment 220
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

Asthma exacerbations leading to emergency department visits or hospitalization are associated with a high risk of recurrent exacerbations, poor disease control, and increased healthcare utilization in the months following discharge. Early specialist follow-up during this vulnerable transition period remains limited, and many patients do not receive optimized long-term asthma management. The purpose of this study is to evaluate whether a structured remote asthma clinic intervention initiated shortly after hospital discharge can reduce recurrent exacerbations and improve asthma-related outcomes compared to standard community care. This prospective randomized study will enroll 220 adult patients (18-75 years) presenting to the emergency department at Tel Aviv Sourasky Medical Center with an asthma exacerbation. Participants will be randomly assigned to one of two groups: 1. Intervention group - will undergo two structured remote pulmonology follow-up visits via secure video consultation within 7-21 days and 5 months after discharge, including treatment optimization, inhaler technique assessment, and self-management education. 2. Control group - will continue standard community care without additional intervention. All participants will complete scheduled follow-up assessments over 12 months, including evaluation of exacerbations, asthma control, healthcare utilization, and medication use.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Other: Follow-up in a remote flare-up clinic — Participants assigned to the intervention group will undergo two structured remote pulmonology visits via secure video consultation, conducted 7-21 days and 5 months after discharge following an asthma exacerbation. The intervention will include assessment of asthma control and exacerbation history, inhaler technique evaluation, treatment optimization, and asthma self-management education according to current guidelines. Additional follow-up phone assessments will be conducted at 3, 9, and 12 months for study outcome evaluation only.

Primary Outcomes

  • Asthma Exacerbations Rate (From enrollment to 3 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-07-01
Completion: 2028-12-31
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 220 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Tel-Aviv Sourasky Medical Center
Collaborators: The Dalia and Eli Hurvitz Foundation Grant
Contact Information
Study Contact:
Amir Bar-Shai
+972-507265248
amirbs@tlvmc.gov.il
Amir Bar-Shai, MD
+972-507265248
amirbs@tlvmc.gov.il
Tel-Aviv Sourasky Medical Center, Tel Aviv
Interventions
  • Other: Follow-up in a remote flare-up clinic — Participants assigned to the intervention group will undergo two structured remote pulmonology visits via secure video consultation, conducted 7-21 days and 5 months after discharge following an asthma exacerbation. The intervention will include assessment of asthma control and exacerbation history, inhaler technique evaluation, treatment optimization, and asthma self-management education according to current guidelines. Additional follow-up phone assessments will be conducted at 3, 9, and 12 months for study outcome evaluation only.
Study Locations (1 sites)
Tel-Aviv Sourasky Medical Center, Tel Aviv, Tel Aviv, Israel
Eligibility Criteria
Inclusion Criteria: * Presentation to the emergency department with an asthma exacerbation. * Ability to complete telephone follow-up and access to a personal e-mail account. * Agreement to participate in the study. * Written or verbal informed consent according to study group assignment. Exclusion Criteria: * Uncontrolled cardiac disease. * Any other uncontrolled medical condition. * Inability to complete telephone follow-up. * Pregnancy. * Patients lacking decision-making capacity.